Clinical trials
Carcinoma, Bronchogenic trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 5 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Blueprint Medicines Corporation | 4 |
| Eli Lilly and Company | 3 |
| Hoffmann-La Roche | 2 |
| Revolution Medicines, Inc. | 2 |
| VA Office of Research and Development | 2 |
| Weill Medical College of Cornell University | 2 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| National Institutes of Health Clinical Center (CC) | 1 |
| NovaRx Corporation | 1 |
| Pharmacyclics LLC. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Bronchogenic | 23 |
| Lung Neoplasms | 21 |
| Carcinoma, Non-Small-Cell Lung | 20 |
| Neoplasms | 20 |
| Neoplasms by Site | 18 |
| Thoracic Neoplasms | 18 |
| Respiratory Tract Diseases | 17 |
| Respiratory Tract Neoplasms | 17 |
| Lung Diseases | 16 |
| Bronchial Neoplasms | 15 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.